Mucocutaneous leishmaniasis complicating systemic lupus erythematosus and responding to high dose amphotericin B

2021 ◽  
Author(s):  
L. Matos ◽  
C. Figueiredo ◽  
F. Alves ◽  
N. Pereira ◽  
M. Gonçalo
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Amphotericin B ◽  
Lupus Erythematosus ◽  
High Dose ◽  
Systemic Lupus ◽  
Mucocutaneous Leishmaniasis

Missed hypereosinophilic syndrome in a critically ill patient with systemic lupus erythematosus

2021 ◽  
Vol 14 (1) ◽  
pp. e236592
Author(s):  
Ying Ling ◽  
Mary Jane Bell ◽  
Lisa Chodirker ◽  
Shirley Lake
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Hypereosinophilic Syndrome ◽  
Clinical Manifestations ◽  
Critically Ill Patient ◽  
Total Leucocyte Count ◽  
High Dose ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Systemic Lupus

A high functioning 74-year-old man with systemic lupus erythematosus presented to the emergency department with acute anxiety. He was found to have elevated cardiac enzymes and admitted to the cardiology service for investigation. In hospital, he developed an erythematous papular rash, and deteriorated to being somnolent and bedridden. He was found to have new multiterritory ischaemic strokes. It was eventually noted that he had persistent eosinophilia, present even on admission, which had been overlooked as the total leucocyte count was normal. Serology for antiphospholipid antibody syndrome (APS) was positive. He was diagnosed with hypereosinophilic syndrome (HES) secondary to new APS, and responded to high-dose steroids. This case highlights the importance of fully evaluating a leucocyte differential to make a diagnosis of HES. We discuss the definition, clinical manifestations, diagnostic approach and management of this important condition.

High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus

Lupus ◽  
2004 ◽  
Vol 13 (2) ◽  
pp. 89-94 ◽  
Author(s):  
I A Lisukov ◽  
S A Sizikova ◽  
A D Kulagin ◽  
I V Kruchkova ◽  
A V Gilevich ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Lupus Erythematosus ◽  
High Dose ◽  
Systemic Lupus

scholarly journals Rate of Adverse Effects of Medium- to High-Dose Glucocorticoid Therapy in Systemic Lupus Erythematosus: A Systematic Review of Randomized Control Trials

2017 ◽  
Vol 37 (6) ◽  
pp. 519-524 ◽  
Author(s):  
Savino Sciascia ◽  
Elisa Mompean ◽  
Massimo Radin ◽  
Dario Roccatello ◽  
Maria J. Cuadrado
Keyword(s):  
Systematic Review ◽  
Systemic Lupus Erythematosus ◽  
Adverse Effects ◽  
Lupus Erythematosus ◽  
Glucocorticoid Therapy ◽  
High Dose ◽  
Randomized Control Trials ◽  
Systemic Lupus ◽  
Randomized Control

Head to head comparison of adverse effects and efficacy between high dose deflazacort and high dose prednisolone in systemic lupus erythematosus: a prospective cohort study

Lupus ◽  
2018 ◽  
Vol 27 (6) ◽  
pp. 890-898 ◽  
Author(s):  
A Ganapati ◽  
R Ravindran ◽  
T David ◽  
B Yadav ◽  
V Jeyaseelan ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Cohort Study ◽  
Adverse Effects ◽  
Prospective Cohort Study ◽  
Lupus Erythematosus ◽  
Prospective Cohort ◽  
High Dose ◽  
Systemic Lupus

Systemic Lupus Erythematosus and Related Disorders

2014 ◽  
pp. 257-270
Author(s):  
Bonnie L. Bermas
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Central Nervous System ◽  
Nervous System ◽  
Lupus Erythematosus ◽  
Immunosuppressive Agents ◽  
Future Research ◽  
High Dose ◽  
Childbearing Age ◽  
Systemic Lupus ◽  
Multisystem Disease

Systemic lupus erythematosus (SLE) is a multisystem disease that preferentially affects women of childbearing age. This disorder is both more common and more severe in individuals of African and Asian ancestry. The etiology of SLE is not well understood, although genetics and environmental stimuli clearly are involved. Whether this disease is caused by a T-cell, B-cell, or other immunologic malfunction is debated, but all would agree that clearly autoantibodies such as antinuclear antibodies and anti–double-stranded DNA contribute to the pathophysiology of this disorder. This multisystem disease can affect the skin, joints, lungs, heart, kidneys, and central nervous system. Most of the morbidity and mortality is from renal and central nervous system (CNS) involvement, although accelerated atherosclerosis has recently been appreciated as a major contributor to disease burden. The treatment of SLE has improved over the past decade with less reliance on high-dose corticosteroids and more emphasis on immunosuppressive agents. It is our hope that future research into the pathophysiology of this disorder and the development of more specific therapy, such as biologics, will improve the outcome of this disease.

Seventy years after Hench’s Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus

Lupus ◽  
2020 ◽  
Vol 29 (10) ◽  
pp. 1155-1167 ◽  
Author(s):  
Guillermo Ruiz-Irastorza ◽  
Amaia Ugarte ◽  
Ioana Ruiz-Arruza ◽  
Munther Khamashta
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Nobel Prize ◽  
Lupus Erythematosus ◽  
Therapeutic Use ◽  
High Dose ◽  
Dependent Manner ◽  
Systemic Lupus ◽  
Early Therapy ◽  
Damage Accrual

In 1950, Hench, Kendall and Reichstein were awarded with the Nobel Prize in Physiology and Medicine for the isolation and first therapeutic use of glucocorticoids. Since then, they have become one of the main agents in the treatment of systemic lupus erythematosus (SLE). The use of high-dose oral glucocorticoids (usually 1 mg/kg/day of prednisone equivalent) have become the rule for treating moderate to severe lupus activity. In addition, tapering schemes have not been well defined, all this leading to prolonged exposures to potentially damaging amounts of glucocorticoids. Several studies have shown that glucocorticoids are a major cause of toxicity in SLE in a dose-dependent manner, with prolonged doses greater than 7.5 mg/day being associated with damage accrual. Thus, there is an urgent need for different therapeutic schedules that can achieve a rapid and durable control of lupus activity while reducing the many unwanted effects of glucocorticoids. Recent data show that pulses of methyl-prednisolone are an effective first-line therapy to treat lupus flares (not only severe ones) without major short or long-term toxicity and allowing a reduction in oral prednisone doses. Universal use of hydroxychloroquine – always recommended, infrequently accomplished – and early therapy with immunosuppressive drugs also help control SLE and reduce prednisone load. Results from observational studies confirm the more rapid achievement of remission and the reduction of long-term damage using these combination schedules with reduced prednisone doses. Seventy years after their first therapeutic use, we are learning to use glucocorticoids in a more efficient and safe manner.

High-dose cyclophosphamide for severe systemic lupus erythematosus

Lupus ◽  
2002 ◽  
Vol 11 (7) ◽  
pp. 405-410 ◽  
Author(s):  
D E Gladstone ◽  
A A Prestrud ◽  
A Pradhan ◽  
M J Styler ◽  
D L Topolsky ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
High Dose ◽  
Systemic Lupus ◽  
Severe Systemic Lupus Erythematosus

scholarly journals High-Dose Intravenous Gamma-Globulin in Systemic Lupus erythematosus

Nephron ◽  
1992 ◽  
Vol 62 (4) ◽  
pp. 465-465 ◽  
Author(s):  
A. Oliet ◽  
E. Hernández ◽  
P. Gallar ◽  
A. Vigil
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Gamma Globulin ◽  
High Dose ◽  
Systemic Lupus ◽  
Intravenous Gamma Globulin
Sign in / Sign up

Export Citation Format

Share Document